MITCHELL JAY RUBIN, M.D. FAAN (cell) Neurology Expert Witness Stroke tpa Emergency Neurology Telemedicine

Transcription

1 Education University of Pennsylvania Philadelphia, Pennsylvania B. A. Summa Cum Laude 1976 Phi Beta Kappa 1977 Pi Gamma Mu (National Social Science Honor Society) 9/1977-5/1981 University of Pennsylvania Philadelphia, Pennsylvania M. D. Post-Doctoral Education 7/1981-6/1982 Internship, Internal Medicine Lankenau Hospital Philadelphia, Pennsylvania 7/1982-6/1984 Resident, Neurology Columbia-Presbyterian Medical Center The Neurological Institute of New York 7/1984-6/1985 Chief Resident, Neurology Columbia-Presbyterian Medical Center The Neurological Institute of New York Certifications National Board of Examiners American Board of Psychiatry and Neurology- Neurology Academic Appointments Visiting Clinical Fellow Columbia University College of Physicians Page 1 of 5

2 Active Licensure Arkansas Arizona California Florida Georgia Indiana Illinois Massachusetts Missouri Montana Nevada New Jersey New York North Carolina Ohio Pennsylvania South Carolina Tennessee Utah Virginia West Virginia Wisconsin Societies Present American Academy of Neurology Present Philadelphia Neurologic Society Employment Moorestown Medical Associates, Moorestown, NJ Staff Neurologist Advocare Neurology of South Jersey Neurology Consultants of Burlington County President 9/2010 8/2013 Medical Director: Neurology Center, Capital Health Trenton NJ Present Specialists on Call Teleneurologist 9/2013 8/2015 Specialists on Call Chairman: Department of Neurology Page 2 of 5

3 Hospital Affiliations 195 hospitals in 22 states as of 8/30/15 List available by request Medical Leadership Chief, Section of Neurology Virtua Memorial Hospital of Burlington County Medical Director, Virtua Stroke Units Virtua Health Systems, New Jersey : Capital Health Systems Director, Emergency Neurology /2013 Capital Health System Medical Director: Neurology Center Committees & Boards Board of Directors Penn Neurocare Delaware Valley Stroke Council Advisory Board : NJ Governor Jim Corzine s Commission on Rationalizing Health Care Resources Member of Subcommittee on Infrastructure and Healthcare Delivery : NJ State Stroke Data Advisory Group : NJ State Evaluation Subcommittee of the Stroke Advisory Panel Page 3 of 5

4 Publications M.J. Binning, G. Sanfillippo, W. Rowen, M. D Ambrosio, E Veznedaroglu, K. Leibman, C Diaz, R Silva, D Eichorn, M, Rubin The Neurological Emergency Room and Prehospital Stroke Alert: The Whole is Greater Than the Sum of Its Parts Neurosurgery 74: , 2014 E. Veznedaroglu, M. Rubin, M, D Ambrosio The Neurological Emergency Room: The Future is Here World Neurosurgery 75 (3/4): March/April A. D. Legatt, M. D., Ph. D.; M. J. Rubin, M. D.; L. R. Kaplan, M. D.; E. B. Healton, M. D.; and J. C. M. Brust, M. D. Global Aphasia Without Hemiparesis: Multiple Etiologies Neurology 1987; 37: Research Sub-Investigator, Bristol Myers Squibb, BMS A Double Blind, Placebo Controlled, Safety, Efficacy and Dose Response Trial of Three Intravenous, Dose of BMS in Patients with Acute Stroke Principle-Investigator, Eli Lilly, B7A-MC-MBBP, B7A-MC-MBBR. Treatment of Peripheral Neuropathy in Patients with Diabetes Sub-Investigator, Glaxo/Smith Kline, LAM A Double Blind, Placebo Controlled, Parallel Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures Sub-Investigator, Shire, Carbatrol SPEQT A Phase IV Study to Evaluate Safety, Preference, Effectiveness Quality of Life, and Tolerability of Switching From Carbamazepine Immediate Release And Liquid formulations to Carbatrol Extended Release Capsules in Epilepsy Subjects Within a Community Based Population Sub-Investigator, Teva Neuroscience PM08. A Multi-center, Open-label, Two Arm Prospective Study to Evaluate the Impact of Patient Readiness to Self-Inject on Outcomes When Using the Copaxone Prefilled Syringes. (The Ready Trial) Principle-Investigator, Novartis, Exelon CENA713Bus13. A Prospective 26 Week Open-Label, Single-Arm, Multi-Center Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) 3-12 mg/day in Patients With Mild to Moderate Alzheimer s Disease Who are Responding Poorly to Aricept (donepexil) Treatment Principle- Investigator, Ono Pharma, USA Inc., Protocol 2506/INT A Randomized, Double Blind, Placebo Controlled, Multi-Center Study of the Effects Of ONO-2506 Intravenous Infusion on the Amelioration of Neurological Damage And Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic Stroke Principle-Investigator, Boehringer Ingelheim, Profess, Trial # A Double Blind, Active and Placebo Controlled Study Of Aggrenox vs Clopidogrel & Aspririn With and Without Micardis. Page 4 of 5

5 2004- Principle- Investigator, AstraZeneca. Protocol Saint-II (Stroke-Acute Ischemic-NXY Treatment). Study code # SA-NXY A double blind, randomized, placebo controlled, parallel group, multi-center, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 in acute ischemic stroke Sub-Investigator, BioMS Technology Corp. Protocol MBP8298-SP-03. A double blind, placebo controlled, multi-center study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis Sub-Investigator, PAREXEL International Protocol- Photo Thera NEST-2. PhotoThera NTS-INT NEST-2 Study: A double blind, randomized, controlled, parallel group, multicenter, pivotal study to assess the efficacy and safety of the treatment of acute ischemic stroke with the NTS Laser System within 24 hours from stroke onset Sub-Investigator, King Pharmaceuticals, Protocol- K A Phase III, Randomized, double blind, parallel, placebo controlled, multi-center study with optional open-label continuation of the efficacy and safety of Vanquix Auto-Injector (Diazepam Injection) for the management of selected, refractory patients with epilepsy who require intermittent medical intervention to control episodes of acute repetitive seizures Sub-Investigator, Bayer HealthCare Pharmaceuticals, Inc. Protocol ; Real-world Betaseron Outcomes Study (ROBUST): A twelve-month, US prospective, observational, open label, single arm, multi-center outcomes study of interferon B-1b (Betaseron) given every other day for relapsing forms of Multiple Sclerosis Sub-Investigator, Eisai Medical Research Inc., Protocol: E2007-G , Investigational Product: E2007. A multi-center, randomized, double- blind, placebo controlled, parallel-group trial to evaluate the efficacy and safety of E2007 in patients with painful diabetic neuropathy. Awards New Jersey Monthly Magazine- TOP DOC in Neurology Philadelphia Magazine- Top Doc In Neurology 2005-Virtua Memorial Hospital - President s Award; Awarded to a Physician Who Has Demonstrated Excellence in Clinical Quality Virtua Health Systems SuperSTAR Award in the category of Physician Excellence. A recognition for achievement in obtaining JCAHO certification for the stroke unit American Stroke Association Get with the Guidelines award recognizing the stroke program of Virtua Memorial for national excellence New Jersey Monthly Magazine- Top Doc in Neurology 2007-South Jersey Magazine: Top Physicians Of South Jersey - Neurology South Jersey Magazine: Top Physicians of South Jersey Neurology 2008 SJ Magazine: Top Docs of South Jersey Neurology 2010 South Jersey Magazine Top Docs of South Jersey - Neurology Page 5 of 5